Tenax Therapeutics enters into amendment to license agreement with Orion Corporation - 8-K ($14.55, 0.00)
Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market (€71.05, 0.00)
Orion Pharma's ODM-212 granted orphan designation for the treatment of malignant mesothelioma by the EU Commission; follows recommendation by EMA's COMP (€68.50, 0.00)
Celltrion notes part 1 approval for European Phase 3 Clinical Trial Plan for CT-P13 SC has expired (KRW 173600.0000, 0)
Orion Pharma announces first results from Phase 1/2 TEADES trial with ODM-212 in patients with advanced solid tumours (30-May) (€71.60, 0.00)
Bayer presents primary results of Phase II ARACOG (AFT-47) head-to-head trial at ASCO; trial met its primary endpoint (€36.53, 0.00)
Orion to present its first clinical data from Phase 1/2 TEADES trial of ODM-212 at the 2026 ASCO Annual Meeting (€71.15, 0.00)
Bayer announces that Primary results from the Phase II ARASEC trial show that NUBEQA plus ADT showed a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in patients with mCSPC (€37.85, -0.33)
FDA approves Tessie for noise aversion and separation anxiety in dogs (€71.00, 0.00)
StreetAccount Summary - Trading higher/lower: EU mid-morning
Powered by FactSet Research Systems Inc.